Developing innovative therapies for degenerative diseases presents scientific and clinical challenges at every stage – from early discovery to clinical application. When rodent models fail to capture the complexity of human aging and degenerations, how do we pinpoint the right indication(s)? When patient populations are highly heterogeneous, how do we identify those most likely to benefit? And when no precedent biomarker methods available for first‑in‑class therapeutics, how do we build up our own toolbox? These challenges have stalled many promising drug candidates at the lab bench or in early clinical stages.
At Sironax, we tackle these translational challenges head-on. We leverage non-human primate models to enhance the relevance and translatability of preclinical data. Through deep collaborations with clinical institutions, we analyze clinical samples from patients and conduct natural history studies, enabling us to identify the most suitable patient subgroups for further clinical development. We established a dedicated biomarker team from the very beginning to develop customized in-house biomarker assays for each program, guiding us through preclinical studies, signal finding in human samples and dosing design for first-in-human clinical studies.
Watch how our scientists navigate the journey from bench to bedside.